Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan
Molecular Genetics & Genomic Medicine · 2026
DOI: 10.1002/mgg3.70204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2026. Verfasst von Hsu-Heng Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Sphingomyelin Phosphodiesterase, Enzyme Replacement Therapy. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Acid sphingomyelinase deficiency (ASMD) is a rare lysosomal disorder with diverse clinical presentations and often delayed diagnosis. This study investigates the clinical features, genetic variants, and treatment outcomes in Taiwanese patients.
Methods
We retrospectively reviewed nine ASMD cases in Taiwan, including genetic data and responses to olipudase alfa. Newborn screening data using the NeoLSD MS/MS kit for dried blood spot enzyme activity, followed by lyso‐sphingomyelin and molecular testing, were also analysed.
Results
The SMPD1 c.1497_1498inv variant was found in 62.5% of alleles among chronic neurovisceral ASMD cases, while c.995C > G appeared in 37.5% of chronic visceral ASMD cases and was also frequent in partial ASMD from newborn screening. Four patients received olipudase alfa; Patient 1, treated for 3 years starting at age 41, showed improved pulmonary function despite persistent thrombocytopenia and splenomegaly. Patients 2, 6, and 7, treated from early childhood, exhibited marked improvements in hepatosplenomegaly, interstitial lung disease, and growth within 1 year of therapy.
Conclusion
This study highlights distinct genotype–phenotype correlations in ASMD and supports the clinical benefits of olipudase alfa. Increased awareness and early diagnosis, potentially through newborn screening, are essential for optimizing outcomes in ASMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pediatrics, Changhua Christian Children's Hospital, Changhua, Taiwan.
- Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Pediatrics, National Taiwan University College of Medicine, Taipei, Taiwan.
- Division of Hematology/Oncology, Veterans General Hospital-Kaohsiung, Kaohsiung, Taiwan.
- Center for Precision Medicine, China Medical University Hospital, Taichung, Taiwan.
Zitieren
APA
Lin, H. H., Chen, H. A., Lin, S. J., Hsu, R. H., Lee, N. C., Hwu, W. L., Ni, Y. H., Chou, Y. Y., Chiu, P. C., Peng, S. S., & Chien, Y. H. (2026). Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70204
Vancouver
Lin HH, Chen HA, Lin SJ, Hsu RH, Lee NC, Hwu WL, et al. Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan. Molecular Genetics & Genomic Medicine. 2026. doi:10.1002/mgg3.70204
BibTeX
@article{Lin2026,
author = {Lin, Hsu-Heng and Chen, Hui-An and Lin, Shyh-Jer and Hsu, Rai-Hseng and Lee, Ni-Chung and Hwu, Wuh-Liang and Ni, Yen-Hsuan and Chou, Yen-Yin and Chiu, Pao-Chin and Peng, Steven Shinn-Forng and Chien, Yin-Hsiu},
title = {Pathogenic Variants and Olipudase Alfa Treatment of Patients With Acid Sphingomyelinase Deficiency in Taiwan},
journal = {Molecular Genetics & Genomic Medicine},
year = {2026},
doi = {10.1002/mgg3.70204}
}
EUVIMED